AI Article Synopsis
- Scientists and doctors need to look at specific traits in glioma tumors to figure out the best diagnosis and treatment.
- New rules from the WHO and FDA show that testing these traits can really help in treating glioma patients.
- Certain gene changes can help doctors use special drugs and find other treatments that could help people with gliomas.
Article Abstract
Purpose Of Review: A number of molecular characteristics are essential for accurate diagnosis and prognostication in glioma.
Recent Findings: The 2021 WHO classification of brain tumors and recent Food and Drug Administration (FDA) pathology agnostic drug approvals highlight the importance of molecular testing in the management of glioma. For diffuse gliomas, it is important to identify IDH mutations, given the favorable clinical behavior and potential for using FDA approved IDH inhibitors in the near future. MGMT promoter methylation testing is the most established molecular marker for response to temozolomide in IDH wild-type glioblastoma and in turn impacts overall survival. Moreover, identification of certain mutations and molecular markers, such as BRAF V600E, hypermutation or elevated tumor-mutational burden and NTRK fusions allow for the use of FDA approved agents that are tumor-agnostic. Finally, molecular testing opens options for clinical trials that are essential for diseases with limited treatment options like gliomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579106 | PMC |
| http://dx.doi.org/10.1007/s11912-024-01602-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!